SEC Company Response from GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — May 11, 2007

GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: May 11, 2007 · CIK: 0000109657 · Accession: 0000109657-07-000015

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-123008, 333-139216

Date

May 9, 2007

Author

Hausman

Form

CORRESP

Company

GT Biopharma, Inc. (GTBP) (CIK 0000109657)

Letter

Division of Corporate Finance Securities and Exchange Commission RE: OXIS International, Inc. Post-Effective Amendments to Form SB-2 Registration Statements Filed May 9, 2007 (File Nos. 333-123008 and 333-139216)

Dear Mr. Belliston:

OXIS International, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (“Commission”) take appropriate action to make the above-captioned registration statement, as amended, be ordered effective as soon as practicable.

The Company acknowledges that:

1. should the Commission or the staff, acting pursuant to delegated authority, declare the filings effective, it does not foreclose the Commission from taking any action with respect to the filings;

2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filings effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filings; and

3. the Company may not assert staff comments and the declaration of effectiveness as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very
truly yours,
/s/
Marvin S.
Hausman

Show Raw Text

CORRESP
1
filename1.htm

      Correspondence

      May
        11,
        2007

      Filed
        as Correspondence Via EDGAR

      Division
        of Corporate Finance

      Securities
        and Exchange Commission

      100
        F.
        Street, N.E.

      Washington,
        D.C. 20549

      Attn:
        Gregory S. Belliston

      RE:
OXIS
        International,
        Inc.

        Post-Effective Amendments to Form SB-2 Registration
        Statements

        Filed May 9, 2007

        (File Nos. 333-123008
        and 333-139216)

      Dear
        Mr.
        Belliston:

      OXIS
        International, Inc. (the “Company”) hereby requests that the Securities and
        Exchange Commission (“Commission”) take appropriate action to make the
        above-captioned registration statement, as amended, be ordered effective
        as soon
        as practicable.

      The
        Company acknowledges that:

      1.  should
        the Commission or the staff, acting pursuant to delegated authority, declare
        the
        filings effective, it does not foreclose the Commission from taking any action
        with respect to the filings;

      2.  the
        action of the Commission or the staff, acting pursuant to delegated authority,
        in declaring the filings effective, does not relieve the Company from its
        full
        responsibility for the adequacy and accuracy of the disclosure in the filings;
        and

      3.  the
        Company may not assert staff comments and the declaration of effectiveness
        as
        defense in any proceeding initiated by the Commission or any person under
        the
        federal securities laws of the United States.

            Very
        truly yours,

            /s/
        Marvin S.
        Hausman

            Marvin
        S. Hausman

            CEO,
        OXIS International,
        Inc.

      cc:
         Edgar
        D.
        Park, Richardson & Patel

SecProbe.io